Document Detail

MedLine Citation:
PMID:  22460118     Owner:  NLM     Status:  MEDLINE    
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
Michael W Stewart; Seden Grippon; Peter Kirkpatrick
Related Documents :
16160788 - Extractive spectrofluorometric determination of quinalphos using fluorescein in environ...
12881018 - Catechin content of 18 teas and a green tea extract supplement correlates with the anti...
8729098 - Determinants of antioxidant status in humans.
10436848 - Comparative in vitro biocompatibility of nickel-titanium, pure nickel, pure titanium, a...
15449238 - Ecological implications of body composition and thermal capabilities in young antarctic...
23816238 - Creating 'obesogenic realities'; do our methodological choices make a difference when m...
Publication Detail:
Type:  News     Date:  2012-03-30
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-30     Completed Date:  2012-06-05     Revised Date:  2013-02-28    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  269-70     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials, Phase III as Topic
Double-Blind Method
Randomized Controlled Trials as Topic
Recombinant Fusion Proteins / adverse effects,  therapeutic use*
United States
United States Food and Drug Administration
Wet Macular Degeneration / drug therapy*
Reg. No./Substance:
0/Recombinant Fusion Proteins; 15C2VL427D/aflibercept

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Defining rewardable innovation in drug therapy.
Next Document:  Novel molecular targets for atrial fibrillation therapy.